Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis - Study Results

Study Type:	Interventional
Study Design:	Randomized, Open Label, Active Control, Parallel Assignment
Condition:	Tuberculosis
Interventions:	Drug: Gatifloxacin Drug: Isoniazid Drug: Levofloxacin Drug: Linezolid Drug: Moxifloxacin

Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Screening for the trial began in February 2004 in Vitória, Brazil. Non-HIV infected adults aged 18-65 years with suspected pulmonary tuberculosis (TB) were recruited at local TB posts and the Hospital Universitario Cassiano Antonio de Moraes of the Universidade Federal do Espírito Santo (UFES) in Vitória. Enrollment was completed in October 2007.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
A total of 113 adults with suspected pulmonary TB were evaluated for study participation. Forty-three were excluded because they did not meet the eligibility criteria, leaving a total of 70 patients.

Reporting Groups

	Description
Gatifloxacin 400 mg/Day	Gatifloxacin 400 mg/day x 7 days
Levofloxacin 1000 mg/Day	Levofloxacin 1000 mg/day x 7days
Linezolid 600 mg / Once Daily	Linezolid 600 mg/once daily x 7days
Linezolid 600 mg / Twice Daily	Linezolid 600 mg twice daily x 7 days
Moxifloxacin 400 mg/Day	Moxifloxacin 400 mg/day x 7 days
Isoniazid (INH) 300 mg/Day	Isoniazid (INH) 300 mg/day x 7 days

Participant Flow: Overall Study

	Gatifloxacin 400 mg/Day	Levofloxacin 1000 mg/Day	Linezolid 600 mg / Once Daily	Linezolid 600 mg / Twice Daily	Moxifloxacin 400 mg/Day	Isoniazid (INH) 300 mg/Day
STARTED	10	10	10	10	10	20
COMPLETED	10	10	10	9	9	18
NOT COMPLETED	0	0	0	1	1	2
Adverse Event	0	0	0	0	1	2
Withdrawal by Subject	0	0	0	1	0	0

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Gatifloxacin 400 mg/Day	Gatifloxacin 400 mg/day x 7 days
Levofloxacin 1000 mg/Day	Levofloxacin 1000 mg/day x 7days
Linezolid 600 mg / Once Daily	Linezolid 600 mg/once daily x 7days
Linezolid 600 mg / Twice Daily	Linezolid 600 mg twice daily x 7 days
Moxifloxacin 400 mg/Day	Moxifloxacin 400 mg/day x 7 days
Isoniazid (INH) 300 mg/Day	Isoniazid (INH) 300 mg/day x 7 days

Baseline Measures

	Gatifloxacin 400 mg/Day	Levofloxacin 1000 mg/Day	Linezolid 600 mg / Once Daily	Linezolid 600 mg / Twice Daily	Moxifloxacin 400 mg/Day	Isoniazid (INH) 300 mg/Day	Total
Number of Participants [units: participants]	10	10	10	10	10	20	70
Age [units: participants]
<=18 years	0	0	0	0	0	0	0
Between 18 and 65 years	10	10	10	10	10	20	70
>=65 years	0	0	0	0	0	0	0
Age [units: years] Median ( Inter-Quartile Range )	34.5 ( 27.0 to 40.0 )	43.5 ( 42.0 to 46.0 )	33.5 ( 23.0 to 42.0 )	45.0 ( 39.0 to 48.0 )	35.0 ( 25.0 to 37.0 )	33.0 ( 23.0 to 43.5 )	35.0 ( 26.0 to 44.0 )
Gender [units: participants]
Female	1	2	2	2	1	3	11
Male	9	8	8	8	9	17	59
Region of Enrollment [units: participants]
Brazil	10	10	10	10	10	20	70

Outcome Measures

Show All Outcome Measures

1. Primary:

Sputum Bacillary Loads: Adjusted Area Under the Curve (aAUC) [ Study drug administration duration - 7 days monotherapy ]

Show Outcome Measure 1

2. Primary:

Difference in Sputum Bacillary Loads: Early Bactericidal Activity (EBA) Days 0 to 2; Fluoroquinolones/Isoniazid (INH) Comparison [ Day 0 to Day 2 Monotherapy ]

Show Outcome Measure 2

3. Primary:

Extended Early Bactericidal Activity (EBA) From Days 2 to 7; Fluoroquinolones/Isoniazid (INH) Comparison [ Day 2 to Day 7 Monotherapy ]

Show Outcome Measure 3

4. Primary:

Sputum Bacillary Loads: Adjusted Area Under the Curve (aAUC) [ Study drug administration duration - 7 days monotherapy ]

Show Outcome Measure 4

5. Primary:

Difference in Sputum Bacillary Loads: Early Bactericidal Activity (EBA) Days 0 to 2; Linezolid Once Daily/Linezolid Twice Daily/Isoniazid (INH) Comparison [ Day 0 to Day 2 Monotherapy ]

Show Outcome Measure 5

6. Primary:

Difference in Sputum Bacillary Loads: Extended Early Bactericidal Activity (EBA) From Days 2 to 7; Linezolid Once Daily/Linezolid Twice Daily/INH Comparison [ Day 2 to Day 7 Monotherapy ]

Show Outcome Measure 6

7. Secondary:

Maximum Plasma Drug Concentration (Cmax) [ Day 5 (7 time points) ]

Show Outcome Measure 7

8. Secondary:

Time to Maximum Plasma Drug Concentration (Tmax) and Half-life [ Day 5 (7 time points) ]

Hide Outcome Measure 8

Measure Type	Secondary
Measure Title	Time to Maximum Plasma Drug Concentration (Tmax) and Half-life
Measure Description	No text entered.
Time Frame	Day 5 (7 time points)
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Thirty-nine patients underwent pharmacokinetic (PK) sampling after receiving 5 daily doses of study drug. One subject in the moxifloxacin arm was discontinued from the study before day 5 and did not undergo PK sampling.

Reporting Groups

	Description
Gatifloxacin 400 mg/Day	Gatifloxacin 400 mg/day x 7 days
Levofloxacin 1000 mg/Day	Levofloxacin 1000 mg/day x 7days
Moxifloxacin 400 mg/Day	Moxifloxacin 400 mg/day x 7 days
Isoniazid (INH) 300 mg/Day	Isoniazid (INH) 300 mg/day x 7 days

Measured Values

	Gatifloxacin 400 mg/Day	Levofloxacin 1000 mg/Day	Moxifloxacin 400 mg/Day	Isoniazid (INH) 300 mg/Day
Number of Participants Analyzed [units: participants]	10	10	9	10
Time to Maximum Plasma Drug Concentration (Tmax) and Half-life [units: hours] Median ( Full Range )
Tmax	1.5 ( 1.0 to 8.0 )	1.0 ( 1.0 to 4.0 )	1.0 ( 1.0 to 2.0 )	1 ( 1.0 to 2.0 )
Half-life	6.0 ( 5.2 to 9.3 )	7.6 ( 4.4 to 19.1 )	8.1 ( 5.1 to 9.9 )	2.5 ( 1.5 to 4.9 )

No statistical analysis provided for Time to Maximum Plasma Drug Concentration (Tmax) and Half-life

9. Secondary:

Maximum Plasma Drug Concentration/Minimum Inhibitory Concentration (Cmax/MIC) [ Day 5 (7 time points) ]

Show Outcome Measure 9

10. Secondary:

Pharmacokinetic Parameters: Area Under the Curve (AUC) During First 12 and 24 Hours [ Day 5 (7 time points) ]

Show Outcome Measure 10

11. Secondary:

Area Under the Curve During First 12 or 24 Hours / Minimum Inhibitory Concentration (AUC/MIC) [ Day 5 (7 time points) ]

Show Outcome Measure 11

12. Secondary:

Maximum Plasma Drug Concentration (Cmax) [ Day 5 (7 time points) ]

Show Outcome Measure 12

13. Secondary:

Time to Maximum Plasma Drug Concentration (Tmax) and Half-life [ Day 5 (7 time points) ]

Show Outcome Measure 13

14. Secondary:

Pharmacokinetic Parameters: Area Under the Curve During First 12 and 24 Hours [ Day 5 (7 time points) ]

Show Outcome Measure 14

15. Secondary:

Maximum Plasma Drug Concentrations (Cmax), Adjusted for Free Drug Concentration [ Day 5 (7 time points) ]

Show Outcome Measure 15

16. Secondary:

Maximum Plasma Drug Concentration/Minimum Inhibitory Concentration (Cmax/MIC) Adjusted for Free Drug Concentrations [ Day 5 (7 time points) ]

Show Outcome Measure 16

17. Secondary:

Area Under the Curve (AUC) During First 12 and 24 Hours Adjusted for Free Drug Concentrations [ Day 5 (7 time points) ]

Show Outcome Measure 17

18. Secondary:

Area Under the Curve (AUC) Adjusted for Free Drug Concentrations/Minimum Inhibitory Concentration (MIC) [ Day 5 (7 time points) ]

Show Outcome Measure 18

19. Secondary:

Percent Dosing Interval Above Minimum Inhibitory Concentration (MIC) [ Day 5 (7 time points) ]

Show Outcome Measure 19

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The small sample size had limited power to detect small differences in EBA between study arms even though we enrolled patients with smear-positive TB and high sputum bacillary burden to improve chances of detecting differences between treatment arms.

Results Point of Contact:

Name/Title: John L. Johnson, M.D.
Organization: Case Western Reserve University, Tuberculosis Research Unit
phone: (216) 368-1949
e-mail: jlj@case.edu

Publications of Results:

Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, Jankus DD, Debanne SM, Charlebois ED, Maciel E, Palaci M, Dietze R. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2006 Jun;10(6):605-12.

Peloquin CA, Hadad DJ, Molino LP, Palaci M, Boom WH, Dietze R, Johnson JL. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2008 Mar;52(3):852-7. Epub 2007 Dec 10.

Dietze R, Hadad DJ, McGee B, Molino LP, Maciel EL, Peloquin CA, Johnson DF, Debanne SM, Eisenach K, Boom WH, Palaci M, Johnson JL. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med. 2008 Dec 1;178(11):1180-5. Epub 2008 Sep 11.

McGee B, Dietze R, Hadad DJ, Molino LP, Maciel EL, Boom WH, Palaci M, Johnson JL, Peloquin CA. Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2009 Sep;53(9):3981-4. Epub 2009 Jun 29.

Responsible Party:	HHS/NIAID/DMID ( Robert Johnson )
Study ID Numbers:	01-553, TBRU 10
Study First Received:	November 3, 2006
Results First Received:	November 19, 2008
Last Updated:	November 19, 2009
ClinicalTrials.gov Identifier:	NCT00396084 History of Changes
Health Authority:	United States: Institutional Review Board; Brazil: National Committee of Ethics in Research; United States: Food and Drug Administration; United States: Federal Government